Autologous bone marrow transplant (ABMT) and stem cell transplantation (ASCT) are important treatment modalities for acute myeloid leukemia (AML). The role of ASCT in first remission patients remains controversial. Phase II and phase III studies demonstrate that patients with favorable-risk cytogenetics benefit from ASCT, with reduction in relapse and improvement in leukemia-free survival (LFS). Patients with poor-risk cytogenetics do not appear to benefit significantly from ASCT and should preferentially be treated with allogeneic transplant. The role of ASCT for patients with intermediate risk disease is uncertain. It appears that ASCT in first remission will improve disease-free survival compared to standard chemotherapy. Sufficient patients who relapse after chemotherapy treatment can be salvaged with ASCT in second remission such that the beneficial effect on overall survival is blunted. ASCT produces equivalent results to ABMT but with reduced morbidity. The collection of stem cells during recovery from intensive dose consolidation therapy appears to be an attractive strategy that can increase the percentage of patients who are able to receive their intended transplant. Consolidation therapy prior to stem cell collection and transplant has been shown to decrease the relapse rate and improve outcomes, but the optimal nature of this consolidation therapy is unknown. For patients with AML in second remission, ABMT/ ASCT offers a substantial salvage rate, and is particularly effective for patients with acute promyelocytic leukemia. Bone Marrow Transplantation (2003) 31, 731-738. doi:10.1038/sj.bmt.1704020 Keywords: autologous stem cell transplantation; acute myeloid leukemia During the last 5 years, autologous transplantation has emerged as another promising approach to improve postremission therapy of AML.
Summary:
Autologous bone marrow transplant (ABMT) and stem cell transplantation (ASCT) are important treatment modalities for acute myeloid leukemia (AML). The role of ASCT in first remission patients remains controversial. Phase II and phase III studies demonstrate that patients with favorable-risk cytogenetics benefit from ASCT, with reduction in relapse and improvement in leukemia-free survival (LFS). Patients with poor-risk cytogenetics do not appear to benefit significantly from ASCT and should preferentially be treated with allogeneic transplant. The role of ASCT for patients with intermediate risk disease is uncertain. It appears that ASCT in first remission will improve disease-free survival compared to standard chemotherapy. Sufficient patients who relapse after chemotherapy treatment can be salvaged with ASCT in second remission such that the beneficial effect on overall survival is blunted. ASCT produces equivalent results to ABMT but with reduced morbidity. The collection of stem cells during recovery from intensive dose consolidation therapy appears to be an attractive strategy that can increase the percentage of patients who are able to receive their intended transplant. Consolidation therapy prior to stem cell collection and transplant has been shown to decrease the relapse rate and improve outcomes, but the optimal nature of this consolidation therapy is unknown. For patients with AML in second remission, ABMT/ ASCT offers a substantial salvage rate, and is particularly effective for patients with acute promyelocytic leukemia. Bone Marrow Transplantation (2003) 31, 731-738. doi:10.1038/sj.bmt.1704020 Keywords: autologous stem cell transplantation; acute myeloid leukemia During the last 5 years, autologous transplantation has emerged as another promising approach to improve postremission therapy of AML. 1 Autologous transplant offers a way to use the antileukemia effectiveness of ablative therapy without the morbidity and mortality of graft-versus-host disease that complicates allogeneic transplant. In addition to improved safety, autologous transplant is also more broadly applicable, potentially allowing the treatment of all patients who achieve remission and extending the age of transplant to 60 or even 70 years.
Despite a wealth of phase II studies as well as some large phase III studies, the role of autologous transplant in the treatment of patients with AML in first remission remains unsettled. A number of phase II studies have produced outcomes that appear superior to those achievable with standard chemotherapy, including high dose ara-C (HDAC). However, the results of phase III studies have been interpreted by some to minimize the role of upfront autologous transplant in first remission. These phase III studies were designed and implemented before the importance of prognostic features, especially cytogenetics, were fully appreciated. Based on our current understanding of heterogeneity of AML and the need to approach treatment with a risk-adapted method, the question no longer appears to be 'What is the best treatment for AML?' but rather determining the best treatment approach for each category of AML.
Autologous bone marrow transplantation (ABMT)
A number of phase II studies of ABMT for AML in CR1 have been performed. [2] [3] [4] [5] In general, overall disease-free survival (DFS) has been 40-60% with TRM of 5-15% and relapse rates of 30-50%. Between 1986 and 1993, our group investigated the use of ABMT for 50 patients with AML in first remission using bone marrow purged with 4-hydroperoxycyclophosphamide (4-HC) using the technique developed at Johns Hopkins. 6, 7 We used an intensified preparative regimen of busulfan 16 mg/kg p.o. plus etoposide 60 mg/kg. With median follow-up of 11.2 (8.9-15.3 years), long-term event-free survival (EFS) is 68% with the latest relapse seen at 23 months (Figure 1 ). Patients with favorable cytogenetics had EFS of 78% compared to 59% in those lacking favorable cytogenetics. However, despite these promising results, this approach did not seem suitable for broad application. Mucosal and skin toxicity were severe, with patients requiring a median of 3 weeks of parenteral nutrition and 5 weeks of narcotic analgesia. Neutropenia was prolonged, with a median of 41 days to reach an absolute neutrophil count (ANC) 41000/ml, and some patients had particularly delayed engraftment. Delayed engraftment from the 4-HC-purged bone marrow appeared to be more severe in patients who received mitoxantrone rather than daunorubicin during remission induction therapy. 8 Although our TRM was acceptably low (4%), we felt that this would not likely be reproduced outside of the single institution setting.
Phase III studies of ABMT for AML
The first large phase III study for AML was conducted by EORTC/GIMEMA between 1986 and 1993 and was reported in 1995. 9 Patients up to age 55 received remission induction therapy with standard dose ara-C plus daunorubicin for 1-2 cycles. Patients in remission then received consolidation therapy with intermediate dose ara-C (IDAC) plus AMSA. Patients with matched sibling donors were assigned to alloBMT and the remainder were randomized to receive either a second course of chemotherapy or ABMT. For the transplant group, bone marrow was harvested following consolidation therapy and was unmanipulated. The preparative regimen used was either total body irradiation (TBI) plus cyclophosphamide or busulfan plus cyclophosphamide (BuCy2). A total of 941 patients were entered and 623 achieved complete remission (CR). Of these 623, 580 received consolidation therapy. Following consolidation, there was substantial dropout of patients, and 422 patients (73% of those receiving consolidation) were either assigned to allogeneic transplant or randomized. After allocation/randomization, an additional 19% of patients dropped out, so that only 343 patients received the intended therapy. The dropout rate was particularly severe in the group randomized to ABMT where only 74% of randomized patients received the treatment compared to 86% receiving alloBMT, and 83% receiving chemotherapy. In the intent to treat analysis, DFS was better in the autologous transplant group than the chemotherapy group, 48 vs 30% (P ¼ 0.05) ( Table 1) . TRM were similar at 9 and 7%, respectively, but the relapse rate was lower in the ABMT group, 41 vs 57%. Despite the improvement in DFS, overall survival (OS) was equivalent in these two arms. This appeared to be because of salvage of patients in the chemotherapy arm who relapsed and subsequently received ABMT. Results in patients assigned to alloBMT were not significantly different from those in the ABMT arm with DFS 55%, TRM 17%, and relapse rate 24%.
The MRC-10 trial accrued patients between 1988 and 1995 and was reported in 1998. 10 The question asked was quite different from that asked in the EORTC/GIMEMA trial. All patients received four initial courses of chemotherapy. Patients with matched sibling donors were then assigned to alloBMT, and the remaining patients were randomized to either receive additional treatment with ABMT or no further therapy. Bone marrow was harvested after the third course of chemotherapy and was unpurged. There was a large dropout of patients with 380 of 1131 first remission patients lacking donors randomized between ABMT and no therapy. Of the 190 patients randomized to ABMT, only 126 (66%) actually received the intended therapy, a dropout rate more severe than in the EORTC/ GIMEMA trial. Based on intent to treat, the ABMT group had a significant improvement in DFS 54 vs 40% (P ¼ 0.04). TRM was 12% in the ABMT group but the relapse rate was lowered from 58 to 37% (P ¼ 0.0007). When only adult patients are considered, the relapse rate was 35% for ABMT vs 53% without. When analyzed according to cytogenetic risk group, ABMT reduced the relapse rate in the favorable group from 49 to 25% (P ¼ 0.02) and in the intermediate-risk group from 59 to 40% (P ¼ 0.04). The relapse rates in the poor-risk group were high and not significantly different (56% ABMT vs 73% no further therapy). DFS by cytogenetic-risk group was statistically superior only in the favorable risk-group, 70 vs 48% (P ¼ 0.04).
ECOG led an American Intergroup trial that entered patients between 1990 and 1995 and was reported in 1998.
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The question asked was similar to that in the EORTC/ GIMEMA trial comparing ABMT to nonablative chemotherapy in patients who had received one consolidation course after entering remission. Patients received remission induction therapy with standard dose ara-C plus idarubicin, and patients in CR then received a modest consolidation cycle with idarubicin and ara-C. Patients with matched sibling donors were allocated to allogeneic transplant, and others were randomized between ABMT and chemotherapy with HDAC. Bone marrow was collected after the single consolidation course and was purged in vitro with 4-HC. The preparative regimen used was BuCy 4. Of the 518 patients in CR, 346 (67%) received consolidation. A total of 113 patients were assigned to allogeneic transplant and 116 and 117 patients were randomized to ABMT vs chemotherapy, respectively. As in the previous phase III studies, there was additional patient drop out after allocation/randomization. This effect was particularly severe in the ABMT group in which only 54% of patients received the assigned treatment, compared to 74% in the EORTC/GIMEMA trial and 66% in the MRC trial. In the intent to treat analysis, there were no significant differences in DFS between the three arms. Comparing alloBMT, ABMT, and chemotherapy, DFS were 43, 35, and 35%, respectively. As expected, the relapse incidence was lowest in the alloBMT arm at 29% compared to 48% for ABMT and 61% for chemotherapy. TRM was highest in the alloBMT arm at 21% compared to 14% for ABT and 3% for chemotherapy.
A follow-up publication analyzed results by cytogeneticrisk group.
12 DFS for patients with favorable cytogenetics was significantly better in ABMT than chemotherapy, 71 vs 35% (P ¼ 0.05). Results in the alloBMT arm were similar to ABMT, with DFS 63%. For patients with poor-risk cytogenetics, results in the allo BMT arm were significantly superior to both other arms with DFS of 44 vs 13-15% in the other two arms (P ¼ 0.04). Results in the intermediaterisk group were counterintuitive with the ABMT group having a trend to lower DFS at 36% compared to 55% for chemotherapy and 52% for alloBMT.
These three large phase III studies that entered more than 3000 patients still have not definitively established the role of ABMT for AML CR1. Two of three studies showed an overall improvement in DFS in the ABMT arm but none showed an improvement in OS ( Table 1) . Two of the studies evaluated the role of ABMT compared to chemotherapy early in the course of treatment, while the MRC study asked whether ABMT following prolonged chemotherapy would improve outcomes compared to no additional treatment. All three studies suffered from considerable patient withdrawal prior to randomization and further patient dropout after randomization; this late withdrawal was particularly problematic in all three studies in the ABMT arm (Table 2 ). This unbalanced patient dropout complicates analysis of the results on an intent to treat basis. Nonetheless, and despite a TRM of 9-14% during ABMT, the improvements in relapse rate were sufficient to produce significant improvements in DFS in two of the three studies. The improvements in DFS were particularly noteworthy in the favorable-risk cytogenetic group (Table 3 ). In poor-risk patients, the results of the ECOG study support alloBMT as the treatment of choice, as do the high relapse rates in the MRC study in patients without donors.
Autologous stem cell transplant (ASCT)
The application of ASCT to AML was explored by Korbling et al. 13 Despite the lack of hematopoietic growth factors used in this pilot study (patients required a median of 10 aphereses), engraftment was markedly superior when compared to ABMT. However, concern was expressed because of a trend towards an increased relapse rate.
Investigators at the City of Hope Medical Center used intensive postremission consolidation therapy with HDAC for 8-10 doses as a method of in vivo purging.
14 Stem cells were collected with G-CSF stimulation during recovery from this intensive consolidation therapy, and patients then proceeded to ASCT using an intensive regimen of TBI, cyclophosphamide, and etoposide. Outcomes were encouraging with 2 year DFS of 49% by intent to treat, and DFS 61% in the patients actually transplanted. In a subsequent study in which idarubicin was added to HDAC consolidation and in which high-dose IL-2 was used after completion of transplant, results appeared even better with projected 2 year DFS of 68% (Stein A, personal communication). 15 Another group has employed this approach of intensive consolidation using IDAC plus either mitoxantrone or etoposide in collecting peripheral blood stem cells under G-CSF stimulation. 16 In 42 first remission patients, DFS was projected at 71%.
Other groups have also explored the use of ASCT.
17,18
The initial concern that the use of ASCT might lead to higher relapse rates than ABMT had been largely answered by two large retrospective studies. The EBMT compared results in 100 patients treated with ASCT to patients treated with either unpurged or purged ABMT. 19 Comparing ASCT to unpurged marrow, TRM, relapse rate, and LFS were remarkably similar. In this analysis, the use of purged bone marrow appeared beneficial with improved LFS and relapse without an increase in TRM. The EORCTC/GIMEMA compared ASCT to ABMT and found similar outcomes with respect to TRM relapse and DFS although with reduced morbidity and resource utilization in the ASCT group. 20 Our group has studied the use of ASCT in AML CR1 using a two-step approach modeled on the concept of in vivo purging of Stein and co-workers 21 We treated 133 patients with a novel intensive consolidation therapy with ara-C 2 g/m 2 BID combined with etoposide 40 mg/kg CIVI on days 1-4, with stem cells collected during hematologic recovery stimulated by G-CSF. We used the same intensive preparative regimen as in our prior ABMT study with busulfan 16 mg/kg p.o. plus etoposide 60 mg/kg. The HDAC/etoposide regimen proved remarkably good at promoting stem cell mobilization. Only 1/131 patients failed to generate a CD34+ cell dose 45 Â 10 6 /kg, and the median CD34+ cell dose was 15 Â 10 6 /kg. Importantly, 91% of patients received the intended ASCT. Engraftment during transplant was rapid with patients reaching ANC 4500/ml at median day +9 resulting in a duration of neutropenia (ANCo500/ml) of 5 days. Platelets recovered to 420 000/ml by day +13 and to 450 000 by day +20. Despite the use of the same preparative regimen as in our ABMT study, nonhematologic toxicity was markedly reduced, presumably because of rapid engraftment. With median follow-up of 5.2 years (2.2-8.1), overall DFS by intent to treat was 55% ( Figure 2) . As in other studies, the major determinant of outcome was cytogenetic-risk group (Figure 3) . DFS for patients in favorable and intermediate categories were 74 and 50%, respectively. The patients with poor-risk cytogenetics, defined narrowly as -7, -5, or complex, did poorly. The effectiveness of this two-step approach to ASCT is now being evaluated in the cooperative group setting by CALGB.
Cytogenetic-risk groups
Cytogenetics has emerged as the dominant prognostic factor for outcome of AML in CR1. 22, 23 Although allogeneic transplant can blunt the adverse effect of poorrisk cytogenetics, this feature still remains a significant risk factor. Three cytogenetic abnormalities have been recognized as constituting a favorable risk group: t(15, 17), t (8, 21) , and inv16q. The remarkable advances in the treatment of APL with t(15,17) have minimized the role of transplantation for APL in first remission. However, the optimal management of patients with t(8,21) and inv16q remains a matter of controversy. Most studies suggest that postremission treatment with nonablative chemotherapy will result in prolonged DFS in 40-50% of these patients although both better and worse outcomes have been reported. 23, 24 The results of ABMT/ASCT for patients with favorable cytogenetics in AML CR1 are remarkably consistent, and all show DFS 470% 7,10,12,21,25-29 (Table 4 ). It appears that ABMT/ASCT is the treatment of choice for patients with this subgroup of AML. Given these results and low TRM associated with ASCT, the role of alloBMT for these patients would appear to be minimal.
The outcome of patients with intermediate-risk AML treated with ABMT/ASCT is not as consistent as those for the favorable-risk patients. In general, EFS is seen in 50% of these patients. 10, 12, 21, 30 Decision making in this patient group is difficult. AlloBMT is a good treatment option for young patients with matched sibling donors and DFS of 50-60% can be expected. The results of chemotherapy appear to be inferior with DFS of 25-35% in most studies. 23 For patients with poor-risk cytogenetics, the outcome with both chemotherapy and ABMT appears to be poor. 10, 12, 21 For the highest risk group of patients with -5, -7, or complex abnormalities, long-term DFS with either approach is o15%. Allogeneic transplant appears to be the treatment of choice for these patients with DFS of 25-35%.
Cytogenetic risk assessment should be used to guide treatment choices based on a risk-adapted approach (Table 5) . Patients with APL are considered separately. Patients with favorable cytogenetics will fare best if treated with ABMT in first remission and patients with high-risk cytogenetics are best treated with alloBMT. For patients in the large intermediate-risk group, the optimal treatment remains to be defined. Outside the clinical trials setting, treatment choices for this group will be influenced by patient age and comorbidities, as well as other diseaserelated variables such as ease of entering initial remission. 
Role of consolidation therapy
The interval between achieving remission and transplant has long been recognized as an important prognostic factor outcome of ABMT for AML. In a large retrospective survey, the relapse rate was exceedingly high (67%) for patients transplanted at an interval o3 months, and this fell to 35% for patients transplanted after an interval 49 months. 31 Whether the beneficial effect of a long interval was because of early relapse of high-risk patients or whether it was surrogate marker for a beneficial effect on consolidation therapy was undetermined. Mehta et al 32 reported that the number of consolidation cycles prior to ABMT was the most significant prognostic factor for outcome. Patients who received X2 courses of consolidation had DFS of 56 vs 15% for those who received less therapy (P ¼ 0.008). An updated report from this group confirms the finding with patients receiving X2 consolidation cycles having DFS of 55 vs 21% (Po0.0001 and significant in multivariable analysis). 33 This same prognostic factor was identified in an EBMT retrospective analysis of ASCT. 19 Patients receiving 42 courses of consolidation had a reduction in relapse risk from 65 to 42%. When the subgroup of patients with rapid achievement of CR (a second important prognostic factor) were analyzed by a number of consolidation courses, those receiving two or more courses had a significant reduction in relapse risk from 62 to 20% (P ¼ 0.008). This finding is consistent with results of another study showing that the import of consolidation was especially significant in favorable subgroup of patients. 26 Recently, Tallman et al 34 reported on a large retrospective analysis of ABMTR/IBMTR. A total of 157 patients who received ABMT with no prior consolidation therapy were compared to 489 patients who received either standard dose or high-dose ara-C. For patients treated with ABMT, prior consolidation was associated with reduced TRM (P ¼ 0.03) and reduced relapse (P ¼ 0.05). Both LFS (P ¼ 0.05) and OFS (P ¼ 0.03) were also improved. For patients treated with ASCT, the favorable impact of consolidation was more pronounced. Although there was no difference in TRM, there was an improvement in relapse rate (P ¼ 0.01), LFS (Po0.01), and OS (Po0.01).
The optimal amount and type of consolidation therapy prior to ABMT/ASCT remains to be determined. Prolongation of postremission therapy prior to transplant entails the risk of patient dropout from toxicity as well as of rapid relapse in high-risk patients who might benefit from transplantation. These risks need to be balanced against the demonstrated positive effect of cytoreduction.
Second remission patients
Once patients have relapsed after initial chemotherapy, further nonablative chemotherapy produces little hope of long-term survival. Allogeneic transplantation is an important treatment option for patients in second remission (CR2) provided that suitable donors can be found. With matched sibling donors, long-term DFS of 30-40% can be expected although with an associated TRM of at least 30%. Autologous transplant has also been widely used for patients in second remission. Meloni et al 35 initially reported on 20 patients treated with ABMT and projected DFS of 52%. An update from this group on 60 patients with longer follow-up reported DFS of 42%. 36 Other groups have reported DFS of 25-40%. 37, 38 The most important prognostic factor for patients undergoing ABMT CR2 appears to be the duration of first remission. Patients with CR1 412 months appear to have improvements in DFS and OS.
Our group has applied the same two-step approach to ASCT for patients in CR2 that we have used in CR1. 39 As in our first remission studies, consolidation with HDAC/ etoposide appears remarkably effective at mobilizing stem cells, even in these heavily treated patients. Of 28 patients, 26 had adequate stem cells grafts with CD34+ dose 45 Â 10 6 /kg, and the median CD34+ cell dose was 13 Â 10 6 /kg. With median follow-up of 5.7 years, EFS is projected at 52%. The most significant prognostic factor for outcome in this pilot study was cytogenetics. All seven patients with t(15,17) remain in remission, whereas EFS for 21 other patients is 38%.
This same treatment approach has been tested by CALGB in 50 CR2 patients. 40 The median age was 47, and 11 patients were over 60. With a median follow-up of 2.2 years, EFS is 25% overall and 30% for those oage 60. CALGB confirmed the excellent stem cell mobilization with this consolidation regimen. Of 48 patients, 47 achieved adequate grafts (CD34+ dose 42 Â 10 6 /kg), and the median CD34 dose was 5.6 Â 10 6 /kg. Engraftment was rapid with ANC 41000/ml at a median day +10, and platelets 420 000 at a median day +14. The CALGB study confirmed the prognostic import of APL, with 12 patients having projected EFS of 74% compared to 22% in other patients. Other studies also support the efficacy of ASCT for patients with APL in CR2.
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Second autologous transplant
The prognosis of patients who relapse following ABMT for AML is usually poor. Allogeneic transplant for such patients is complicated by a very high rate of TRM. de la Rubia et al. 45 reported on the use of ABMT for patients who relapsed after an initial ASCT. During their initial trials of stem cell transplantation, back-up bone marrow was harvested initially as a precaution in case of graft failure. In all, 18 patients were treated, 17 in untreated relapse. The preparative regimen for first transplant was BuCy 4, and for second transplant was BAVC (with BCNU 800 mg/m 2 ). Results in this study were surprisingly good. Only two of 18 patients (11%) died of treatment-related Table 5 Expected disease-free survival (DFS) with treatments for AML in first remission by cytogenetic-risk group
Risk group
Chemotherapy (%) ABMT (%) Allogeneic BMT (%) complications, and 36% of patients remained in remission at 3 years. The major prognostic factor was the interval between the first transplant and relapse. Patients who relapsed at an interval 47 months had DFS of 52% compared to 20% for those with rapid relapse (P ¼ 0.02). The EBMT confirmed the potential usefulness of second autologous transplant. 46 In all, 56 patients with AML were reported with a median age of 26 years. TRM was 33%, relapse rate 50%, and 2-year LFS at 35%. A favorable effect was seen when bone marrow was harvested in second remission rather than first remission, with reduction in relapse risk from 69 to 22% (P ¼ 0.01), and improvement in LFS from 21 to 55% (P ¼ 0.03). Other favorable prognostic factors included age 426 years with TRM of 44 vs 25% (P ¼ 0.016), transplant in remission rather than relapse with LFS of 44 vs 25% (P ¼ 0.009), and interval from first transplant to relapse 47 months with LFS of 40 vs 28% (P ¼ 0.02). In summary, second autologous transplant appears to be a reasonable treatment option, especially for young patients with a long interval from first transplant to relapse.
The role of purging
Despite extensive experience over a number of years, the role of purging in ABMT for AML remains unsettled. Definitive evidence exists that the graft can contribute to relapse, but the majority of relapses likely occur from systemic disease which is not eradicated by high-dose systemic therapy. The most extensive purging experience is with the use of either 4-HC or mafosfamide to treat bone marrow. Data from phase II studies and retrospective comparisons suggest an advantage for purging, but no phase III studies have directly tested the issue. 31 , 47 Gorin et al 31 reviewed a large number of patients and found that purging reduced the relapse rate from 59 to 40% (P ¼ 0.05). When the analysis was restricted to patients transplanted o6 months from remission, the results were more significant with reduction in relapse rate from 70 to 40% (P ¼ 0.002). Adjusted-dose mafosfamide, based on in vitro assay, appeared to provide some additional advantage over the use of a fixed dose. A retrospective case comparison performed by ABMTR on 294 patients also demonstrated an advantage to purging with 4-HC. 48 For patients in CR1, purging was associated with a decrease in relapse rate from 42 to 34% and improvement in 3 year LFS from 31 to 56%. The effect was more marked in CR2 patients, with relapse 35 vs 55% and 3 year LFS 39 vs 10%. For the entire group, purging was associated with a decreased risk of treatment failure in multivariate analysis.
Despite the evidence that 4-HC purging can decrease relapse rates and improve outcomes, the data have never been convincing enough to generate approval of the drug, and it remains currently unavailable. Interest in 4-HC purging has been hampered by the problem of a marked delay in engraftment. The use of 4-HC-purged bone marrow causes prolonged neutropenia, often up to 6 weeks, resulting in prolonged hospitalization, increased resource utilization and expense. Even if 4-HC were currently available, these engraftment issues create practical problems that might limit its use. It is possible that the use of peripheral blood stem cells would overcome the problem of delayed engraftment after 4-HC purging. Experience in two patients suggests that engraftment will not be markedly delayed. 49 However, experience is limited, and some anecdotal reports create concern about engraftment problems (Miller CB, personnel communication) .
Some groups have used antibody based purging rather than using chemotherapy. Ball et al 50 have reported on the use of monoclonal antibodies directed against CD14 and CD15, and have shown that this can be done safely. Others have used IL-2 incubation of marrow or stem cells to effect an immunologic purge. [51] [52] [53] At this time, there is no generally accepted method of effective purging.
Post-transplant immunomodulation
In the setting of allogeneic transplant, it is recognized that an alloimmune graft vs leukemia effect plays a significant role in long-term leukemia control. This has spurred interest in generating an autologous graft vs leukemia effect after ABMT for AML. Investigators at the City of Hope have used a brief course of high-dose IL-2 after ASCT for AML. 15 They have demonstrated that this can be done safely with morbidity but no mortality. Comparing results in IL-2-treated patients to those of a previous cohort of patients treated with a similar regimen but without IL-2, there was a suggestion of decrease in relapse rate. CALGB is currently conducting a phase III study of prolonged lowdose IL-2 after ASCT for AML. A previous phase I study showed that the low-dose IL-2 regimen was safe and feasible. 54 Linomide was developed as an oral immunomodulator that had IL-2 like effects in stimulating natural killers cells. A phase III study involving 266 patients was conducted and showed good patient tolerance and safety but no effect on relapse rate or LFS. 55 Studies of other post-transplant immune modulation strategies such as vaccination are in their early stages.
Conclusion and future direction
Autologous transplantation is an important treatment modality in the treatment of AML and interest in this area remains high. Appropriate patient selection based on a riskadapted strategy is important for the proper application or study of this treatment modality. Patients with favorable cytogenetics appear to derive significant benefit whereas patients with very high-risk cytogenetics should preferentially be treated with allogeneic transplant when this modality is available. Outside the setting of clinical trials, ABMT/ASCT for intermediate-risk patients is an appropriate treatment choice and seems to improve outcomes compared to conventional chemotherapy. The choice between autologous and allogeneic transplant in this patient group involves consideration of several factors including age, performance status, donor availability, and risk-assessment of the leukemia based on factors other than cytogenetics.
ASCT is likely to replace ABMT based on reduction in morbidity, resource utilization, and duration of hospitalization. Postremission consolidation therapy prior to stem cell collection appears to be very important. The optimal nature and duration of consolidation prior to stem cell collection remain to be determined. Even with the in vivo purging based on prior cytoreduction therapy, the risk of leukemia contamination of stem cells remains. Hopefully effective and nontoxic methods of in vitro purging will be developed. The other area of active interest and research is that of post-transplant immunomodulation aiming at generating an autologous graft vs leukemia effect.
